文献速递细菌感染、耐药与抗菌药物

探究磷霉素的潜力:假体关节感染表皮葡萄球菌的药敏试验与耐药性研究

Probing fosfomycin's potential: a study on susceptibility testing and resistance in Staphylococcus epidermidis from prosthetic joint infections.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究对瑞典假体关节感染中前瞻性收集的89株表皮葡萄球菌(其中74株为耐多药)进行磷霉素表型和基因型药敏分析,发现除1株MIC>256 mg/L外磷霉素抑制所有分离株,fosB仅存在于表型耐药株,商业琼脂稀释面板与金标准基本一致率为84%。

要点

  • 耐多药表皮葡萄球菌占74/89(83%),磷霉素除1株MIC>256 mg/L外抑制所有分离株。
  • 商业琼脂稀释面板与金标准基本一致率84%,倾向于高估MIC。
  • 常用全基因组测序工具提示所有分离株基因型耐药,但fosB仅见于表型耐药株。

核心结论

  • 本研究中磷霉素表型耐药和fosB存在均罕见,提示磷霉素可作为表皮葡萄球菌的治疗选择。
  • 商业琼脂稀释面板重现性高,但与参考方法的基本一致率欠佳。
  • 使用常用全基因组测序工具判读基因型磷霉素耐药时应批判性评估,并用表皮葡萄球菌相关fosB参考序列适当验证。

研究设计与样本

  • 对瑞典假体关节感染中前瞻性收集的表皮葡萄球菌分离株进行研究。
  • 采用内部琼脂稀释法和商业琼脂稀释面板测定MIC。
  • 分析磷霉素耐药相关基因及基因变异。

主要发现

  • 74/89(83%)分离株为耐多药表皮葡萄球菌。
  • 磷霉素抑制所有分离株,仅1株MIC>256 mg/L。
  • 商业琼脂稀释面板与金标准的基本一致率为84%,倾向于高估MIC。
  • 常用全基因组测序工具提示所有分离株基因型磷霉素耐药,但深入分析显示fosB仅存在于表型耐药分离株。
  • 未检测到其他磷霉素耐药相关基因或基因变异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited treatment options for prosthetic joint infections (PJI) due to multidrug-resistant Staphylococcus epidermidis (MDRSE). Fosfomycin (FOF) has gained attention as a potential therapy, but there is a paucity of information on the phenotypic and genotypic susceptibility amongst S. epidermidis, including MDRSE. OBJECTIVES: To investigate phenotypical and genotypical susceptibility to FOF in S. epidermidis isolates prospectively collected from PJIs in Sweden. METHODS: MIC determination was performed using in-house agar dilution (AD) and a commercial AD panel. Genes and gene variants associated with FOF resistance were analysed. RESULTS: Multidrug resistance was common [74/89 (83%) isolates were MDRSE].FOF inhibited all isolates except one, which had an MIC > 256 mg/L. The commercial AD panel demonstrated good overall performance but tended to overestimate the MIC, resulting in 84% essential agreement with the gold standard. Genomic analysis with publically available tools for whole-genome sequencing (WGS) data suggested genotypic FOF resistance in all isolates, but in-depth analysis revealed that fosB, associated with FOF resistance, was only present in the phenotypically resistant isolate. No other genes or gene variants associated with FOF resistance were detected. CONCLUSIONS: Phenotypic resistance to FOF and presence of fosB were rare in this collection, indicating FOF's potential as a treatment option for S. epidermidis. The commercial AD panel demonstrated high reproducibility, but EA with the reference method was less than optimal. Findings of genotypic FOF resistance using common tools for WGS data should be critically evaluated and appropriately verified with relevant fosB references for S. epidermidis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Widerström R, Aarris M, Jacobsson S, et al. Probing fosfomycin's potential: a study on susceptibility testing and resistance in Staphylococcus epidermidis from prosthetic joint infections. J Antimicrob Chemother. 2024. PMID: 39240536. doi:10.1093/jac/dkae312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。